Form 4: Lifecore Biomedical Director Calloway Acquires 30,000 Shares of Common Stock

Director Nathaniel Calloway acquired 30,000 shares of Lifecore Biomedical common stock on July 8, 2024, increasing his total holdings to 58,069 shares.

Summary

• On July 8, 2024, Nathaniel Calloway, a director of Lifecore Biomedical, Inc., acquired 30,000 shares of common stock.
• The acquisition was made directly.
• Following the transaction, Calloway's total beneficial ownership of Lifecore Biomedical common stock increased to 58,069 shares.
• The acquired securities are restricted stock units that convert into common stock on a 1-for-1 basis.
• The restricted stock units vest on the earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. A director purchasing shares is generally a good sign, but the document is simply a regulatory filing detailing the transaction.

Positives

• A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The restricted stock units vest on the earlier of the first anniversary of the grant date or the date of the annual meeting of stockholders first held in calendar year 2025, subject to potential acceleration.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (directors, officers, and 10% owners) of a publicly traded company buy or sell the company's securities. These filings provide transparency to the market regarding insider transactions.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as insider buying is often viewed favorably.

Key Dates